Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure

doi:10.1128/AAC.04987-14

. 2015;59(6):3637-40.

doi: 10.1128/AAC.04987-14. Epub 2015 Mar 30.

Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure

Bo-Huang Liou¹, Yi-Tzu Lee², Shu-Chen Kuo³, Po-Yu Liu⁴, Chang-Phone Fung⁵

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Hsinchu Mackay Memorial Hospital, Hsinchu City, Taiwan.
² Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
³ Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan ludwigvantw@gmail.com.
⁴ Division of Infectious Diseases, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
⁵ Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

PMID: 25824230
PMCID: PMC4432115
DOI: 10.1128/AAC.04987-14

Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure

Bo-Huang Liou et al. Antimicrob Agents Chemother. 2015.

. 2015;59(6):3637-40.

doi: 10.1128/AAC.04987-14. Epub 2015 Mar 30.

Authors

Bo-Huang Liou¹, Yi-Tzu Lee², Shu-Chen Kuo³, Po-Yu Liu⁴, Chang-Phone Fung⁵

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Hsinchu Mackay Memorial Hospital, Hsinchu City, Taiwan.
² Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
³ Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan ludwigvantw@gmail.com.
⁴ Division of Infectious Diseases, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
⁵ Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

PMID: 25824230
PMCID: PMC4432115
DOI: 10.1128/AAC.04987-14

Abstract

We describe the clinical outcome of 17 patients with secondary Acinetobacter bacteremia whose isolates had a tigecycline MIC of ≤2 mg/liter and who received tigecycline within 2 days of bacteremia onset. The 14-day mortality rate of the tigecycline cohort was 41.2% (7/17), which was significantly higher than that of those receiving other appropriate antimicrobial agents (13.8%, 9/65; P = 0.018). However, the percentages of end-stage renal disease and congestive heart failure were higher in the tigecycline cohort. The efficacy of tigecycline was contingent upon the illness severity and bacterial species. Tigecycline should be applied cautiously for treatment of Acinetobacter bacteremia.

PubMed Disclaimer

Cited by

Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy.
Lee YT, Wang YC, Kuo SC, Chen CT, Liu CP, Liu YM, Chen TL, Yang YS. Lee YT, et al. Antimicrob Agents Chemother. 2017 Aug 24;61(9):e00931-17. doi: 10.1128/AAC.00931-17. Print 2017 Sep. Antimicrob Agents Chemother. 2017. PMID: 28674056 Free PMC article.
Efficacy of intravenous tigecycline in patients with Acinetobacter complex infections: results from 14 Phase III and Phase IV clinical trials.
Tucker H, Wible M, Gandhi A, Quintana A. Tucker H, et al. Infect Drug Resist. 2017 Nov 3;10:401-417. doi: 10.2147/IDR.S143306. eCollection 2017. Infect Drug Resist. 2017. PMID: 29138583 Free PMC article.
High-Dose versus Standard-Dose Tigecycline Treatment of Secondary Bloodstream Infections Caused by Extensively Drug-Resistant Acinetobacter baumannii: An Observational Cohort Study.
Han H, Qin W, Zheng Y, Cao D, Lu H, Zhang L, Cui Y, Hu Y, Li W, Guo H, Wu D, Li C, Wang H, Chen Y. Han H, et al. Infect Drug Resist. 2021 Sep 18;14:3837-3848. doi: 10.2147/IDR.S322803. eCollection 2021. Infect Drug Resist. 2021. PMID: 34566417 Free PMC article.
Characterization of Extremely Drug-Resistant and Hypervirulent Acinetobacter baumannii AB030.
Singh M, De Silva PM, Al-Saadi Y, Switala J, Loewen PC, Hausner G, Chen W, Hernandez I, Castillo-Ramirez S, Kumar A. Singh M, et al. Antibiotics (Basel). 2020 Jun 17;9(6):328. doi: 10.3390/antibiotics9060328. Antibiotics (Basel). 2020. PMID: 32560407 Free PMC article.
Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia.
Kang FY, How CK, Wang YC, Cheng A, Yang YS, Kuo SC, Liu CP, Liu YM, Chen TL, Lee YT. Kang FY, et al. Antimicrob Resist Infect Control. 2020 Sep 29;9(1):160. doi: 10.1186/s13756-020-00824-4. Antimicrob Resist Infect Control. 2020. PMID: 32993810 Free PMC article.

See all "Cited by" articles

References

1. Gardiner D, Dukart G, Cooper A, Babinchak T. 2010. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 50:229–238. doi:10.1086/648720. - DOI - PubMed
1. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41(Suppl):S341–S353. doi:10.1086/431675. - DOI - PubMed
1. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(Suppl):S354–S367. doi:10.1086/431676. - DOI - PubMed
1. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R. 2009. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 63:52–61. doi:10.1016/j.diagmicrobio.2008.09.001. - DOI - PubMed
1. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R. 2008. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 61:329–338. doi:10.1016/j.diagmicrobio.2008.04.009. - DOI - PubMed

Publication types

Actions

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Gardiner D, Dukart G, Cooper A, Babinchak T. 2010. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 50:229–238. doi:10.1086/648720. - DOI - PubMed

[2] Gardiner D, Dukart G, Cooper A, Babinchak T. 2010. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 50:229–238. doi:10.1086/648720. - DOI - PubMed

[3] Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41(Suppl):S341–S353. doi:10.1086/431675. - DOI - PubMed

[4] Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. 2005. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41(Suppl):S341–S353. doi:10.1086/431675. - DOI - PubMed

[5] Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(Suppl):S354–S367. doi:10.1086/431676. - DOI - PubMed

[6] Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(Suppl):S354–S367. doi:10.1086/431676. - DOI - PubMed

[7] Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R. 2009. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 63:52–61. doi:10.1016/j.diagmicrobio.2008.09.001. - DOI - PubMed

[8] Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R. 2009. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 63:52–61. doi:10.1016/j.diagmicrobio.2008.09.001. - DOI - PubMed

[9] Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R. 2008. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 61:329–338. doi:10.1016/j.diagmicrobio.2008.04.009. - DOI - PubMed

[10] Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R. 2008. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 61:329–338. doi:10.1016/j.diagmicrobio.2008.04.009. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure

Affiliations

Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical